A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs TKM PLK1 (Primary)
  • Indications Adrenocortical carcinoma; Hodgkin's disease; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Tekmira Pharmaceuticals Corporation
  • Most Recent Events

    • 07 Jun 2016 Results (n=16) assessing safety and efficacy, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 27 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 14 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top